Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab + R2 in Relapsed or Refractory Follicular Lymphoma
NCT05409066Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Sep 2022
- Primary completion
- Dec 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 30
01
Overview
Phase 3, randomised, open-label trial of epcoritamab in follicular lymphoma (FL) (3 arms), sponsored by Genmab. Primary endpoints: Best Overall Response at 27 months and Progression-Free Survival at 27 months. Started Sep 2022; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05409066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05409066.